StockData
Moderna, Inc. logo

Moderna, Inc.

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)

Close on Nov 2, 2026Market cap $88.16BP/E –Yield –

Moderna Cumulative latent virus, rare disease & other by Quarter

Cumulative latent virus, rare disease & other therapeutic trials (trials)

QuarterlyAnnual

Moderna Cumulative latent virus, rare disease & other: 43.00 trials in Q2 2026, up 10.3% from a year earlier. That is the highest of the 34 quarters on record here.

Latest, Q2 2026
43.00
Period ended Jun 30, 2026
Change on a year earlier
+10.3%
39.00 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
1
ClinicalTrials.gov API v2 (ModernaTX, Inc.)

Where the Q2 2026 figure comes from

Source: ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗

Reported in ClinicalTrials.gov API v2 (ModernaTX, Inc.).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCumulative latent virus, rare disease & other therapeutic trials (trials)Year on yearSource
Q2 2026Jun 30, 202643.00+10.3%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2026Mar 31, 202642.00+10.5%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2025Dec 31, 202541.00+7.9%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2025Sep 30, 202540.00+11.1%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q2 2025Jun 30, 202539.00+11.4%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2025Mar 31, 202538.00+8.6%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2024Dec 31, 202438.00+18.8%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2024Sep 30, 202436.00+12.5%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q2 2024Jun 30, 202435.00+29.6%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2024Mar 31, 202435.00+40.0%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2023Dec 31, 202332.00+33.3%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2023Sep 30, 202332.00+45.5%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q2 2023Jun 30, 202327.00+28.6%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q1 2023Mar 31, 202325.00+31.6%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q4 2022Dec 31, 202224.00+33.3%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Q3 2022Sep 30, 202222.00+69.2%ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗

Cite this data

StockData. (2026). Moderna Cumulative latent virus, rare disease & other, quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ctgov-cum-latent-other

See every metric in the Moderna KPI table. Data updated Nov 3, 2026.